The phase III AURA3 study further examined osimertinib compared to platinum/pemetrexed chemotherapy in 419 T790M-positive advanced NSCLC patients who had progressed to first generation EGFR-TKIs. Here, EGFR is linked to non-small cell lung carcinoma.